Athenex Ruling Helps Clarify FDA Drug Compounding Policy

Health Care & Life Sciences partner Nate Brown authors article with Law30 on Athenex ruling and its impact on clarifying the FDA drug compounding policy.
Excerpt from Law360:
On Aug. 1, 2019, the U.S. District Court for the District of Columbia affirmed the U.S. Food and Drug Administration's decision to exclude the bulk drug substance vasopressin from the agency's List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act, or 503B bulks list, in Athenex Pharma Solutions LLC v. Azar II.
For the full article, click here.